{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Parmax Pharma Q4 FY26: Mounting Losses Signal Deepening Crisis
Parmax Pharma Ltd., a micro-cap pharmaceutical company specialising in Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations (CMO), reported a net loss of ₹0.58 crores for Q4 FY26 (Jan-Mar'26), marking the seventh consecutive quarter of losses. Whilst the loss narrowed sequentially from ₹0.73 crores in Q3 FY26, it remains significantly lower than the ₹1.49 crores loss in Q4 FY25. The company's shares surged 16.88% to ₹52.00 following the results, despite the troubling financial performance, suggesting speculative trading rather than fundamental improvement.
Broad-Based Technical Strength Lifts Parmax Pharma Ltd to 52-Week High of Rs 53.38
With a surge to Rs 53.38 on 4 Jun 2026, Parmax Pharma Ltd has reached a fresh 52-week high, propelled by a striking alignment of technical indicators and sustained price momentum that outpaces its sector and the broader market.
When is the next results date for Parmax Pharma Ltd?
The next results date for Parmax Pharma Ltd is June 2, 2026.
Are Parmax Pharma Ltd latest results good or bad?
Parmax Pharma Ltd's latest results are concerning, showing a 72.74% decline in net sales year-on-year and a net loss of ₹0.73 crores, indicating significant operational distress and balance sheet deterioration. The company faces critical challenges in maintaining its market position and financial stability.
Parmax Pharma Ltd Falls to 52-Week Low of Rs 22.6 as Sell-Off Deepens
Parmax Pharma Ltd’s share price declined sharply to a new 52-week low of Rs.22.6 on 25 March 2026, marking a significant downturn amid broader market gains. The stock underperformed its sector and key moving averages, reflecting ongoing financial pressures and subdued performance metrics.
Parmax Pharma Ltd Falls to 52-Week Low of Rs 24.5 Amidst Continued Weakness
Parmax Pharma Ltd, a micro-cap entity in the Pharmaceuticals & Biotechnology sector, has declined sharply to a new 52-week low of Rs.24.5, marking a significant drop of 11.71% in today’s trading session. This fresh low underscores the stock’s ongoing underperformance relative to its sector and broader market indices.
Parmax Pharma Ltd Falls to 52-Week Low of Rs 25 Amidst Weak Financials
Parmax Pharma Ltd’s shares declined sharply to a new 52-week low of Rs.25 on 12 Mar 2026, marking a significant downturn amid ongoing financial headwinds and sector underperformance. The stock’s recent volatility and sustained downward trend reflect persistent challenges in the company’s financial metrics and market positioning.
Parmax Pharma Q3 FY26: Mounting Losses Deepen as Revenue Plummets 72% YoY
Parmax Pharma Ltd., a micro-cap pharmaceutical company specialising in Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations (CMO), has reported deeply concerning financial results for Q3 FY26, with net losses widening to ₹0.73 crores whilst revenues collapsed 72.74% year-on-year to ₹2.53 crores. The company, trading at ₹32.00 with a market capitalisation of just ₹12.00 crores, has now recorded consecutive quarterly losses throughout FY26, raising serious questions about operational viability and management execution.
When is the next results date for Parmax Pharma Ltd?
The next results date for Parmax Pharma Ltd is 14 February 2026.
Parmax Pharma Ltd is Rated Strong Sell
Parmax Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 16 June 2025, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are based on the company’s current position as of 26 December 2025, providing investors with the latest comprehensive analysis.
Why is Parmax Pharma falling/rising?
On 19-Dec, Parmax Pharma Ltd witnessed a sharp decline in its share price, falling by 7.82% to close at ₹31.00. This drop reflects a continuation of the stock’s underperformance relative to the broader market and is underpinned by weak financial results and deteriorating fundamentals.
Parmax Pharma’s Evaluation Revised Amidst Challenging Financial and Market Conditions
Parmax Pharma has undergone a revision in its market assessment reflecting a more cautious outlook due to recent financial and technical developments. The pharmaceutical company’s evaluation metrics have shifted downward, influenced by deteriorating fundamentals and market performance indicators.
Parmax Pharma Stock Falls to 52-Week Low of Rs.28 Amidst Weak Financials
Parmax Pharma's shares touched a fresh 52-week low of Rs.28 today, marking a significant decline amid subdued financial performance and persistent volatility. The stock's intraday fall of 10.26% outpaced the Pharmaceuticals & Biotechnology sector, reflecting ongoing challenges within the company’s fundamentals.
How has been the historical performance of Parmax Pharma?
Parmax Pharma has experienced fluctuating financial performance, with net sales increasing from 11.05 Cr in Mar'24 to 28.20 Cr in Mar'25, but facing ongoing profitability challenges, including negative profits after tax of -2.09 Cr in Mar'25 and deteriorating reserves of -6.44 Cr. Despite revenue growth, the company struggles with liquidity and a rising debt burden.
How has been the historical performance of Parmax Pharma?
Parmax Pharma's historical performance shows fluctuating net sales, increasing from INR 11.05 crore in March 2024 to INR 28.20 crore in March 2025, but it continues to face profitability challenges with negative profit before tax and reserves. Despite growth in sales, the company reported an operating profit of INR 0.25 crore in March 2025, recovering from a loss the previous year.
Why is Parmax Pharma falling/rising?
As of 07-Nov, Parmax Pharma Ltd's stock price is declining at 32.60, down 1.21%, and has fallen 6.19% over the last three days. It is trading below all major moving averages, with a significant drop in delivery volume, indicating a persistent downward trend compared to the broader market.
Why is Parmax Pharma falling/rising?
As of 31-Oct, Parmax Pharma Ltd's stock price is Rs 34.50, up 7.81% today, but it has a year-to-date decline of 22.03%. While it has recently outperformed the Sensex, its long-term performance remains weak compared to the broader market.
Why is Parmax Pharma falling/rising?
As of 29-Oct, Parmax Pharma Ltd's stock price is Rs 31.05, down 10.39%, and has underperformed significantly with a year-to-date decline of 29.83%. The stock is trading below all major moving averages, indicating a bearish trend and a lack of investor interest.
Why is Parmax Pharma falling/rising?
As of 27-Oct, Parmax Pharma Ltd's stock price is at 34.99, up 6.0% today, but it has underperformed year-to-date with a decline of 20.93%. Despite recent gains and increased investor interest, the stock lags behind broader market performance.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
